Hamel Associates Inc. acquired a new position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,003 shares of the company’s stock, valued at approximately $646,000.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Amundi grew its position in shares of AstraZeneca by 6.7% in the second quarter. Amundi now owns 16,422,784 shares of the company’s stock valued at $3,114,088,000 after purchasing an additional 1,036,635 shares during the period. Janus Henderson Group PLC increased its stake in shares of AstraZeneca by 889.9% during the first quarter. Janus Henderson Group PLC now owns 11,949,424 shares of the company’s stock worth $2,319,947,000 after purchasing an additional 10,742,268 shares in the last quarter. Fisher Asset Management LLC raised its position in shares of AstraZeneca by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 11,501,748 shares of the company’s stock worth $1,857,187,000 after purchasing an additional 355,456 shares during the last quarter. Royal Bank of Canada raised its position in shares of AstraZeneca by 208.6% during the 1st quarter. Royal Bank of Canada now owns 10,386,455 shares of the company’s stock worth $2,048,417,000 after purchasing an additional 7,021,126 shares during the last quarter. Finally, Rathbones Group PLC lifted its stake in AstraZeneca by 106,772.0% in the 1st quarter. Rathbones Group PLC now owns 8,054,943 shares of the company’s stock valued at $1,560,419,000 after buying an additional 8,047,406 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.
AstraZeneca Stock Performance
AZN opened at $184.66 on Monday. The firm has a market capitalization of $286.40 billion, a PE ratio of 26.12, a PEG ratio of 1.43 and a beta of 0.24. AstraZeneca Plc has a twelve month low of $153.41 and a twelve month high of $212.71. The firm’s 50-day moving average price is $168.82 and its 200 day moving average price is $180.20. The company has a current ratio of 1.01, a quick ratio of 0.79 and a debt-to-equity ratio of 0.51.
AstraZeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings data on Saturday, October 31st. The company reported $2.79 EPS for the quarter, beating analysts’ consensus estimates of $2.60 by $0.19. The company had revenue of $16.21 billion during the quarter, compared to the consensus estimate of $16 billion. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. AstraZeneca’s quarterly revenue was up 6.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.38 EPS. As a group, sell-side analysts expect that AstraZeneca Plc will post 10.22 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts recently issued reports on AZN shares. Deutsche Bank upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, September 15th. Nordea Equity Research raised AstraZeneca from a “sell” rating to a “buy” rating in a report on Tuesday, October 13th. Citigroup reissued a “buy” rating on shares of AstraZeneca in a report on Tuesday, October 6th. Zacks Research upgraded AstraZeneca from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 13th. Finally, Wall Street Zen raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $206.67.
Check Out Our Latest Report on AstraZeneca
About AstraZeneca
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Further Reading
- Five stocks we like better than AstraZeneca
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
